Previous 10 | Next 10 |
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare ...
The pharmaceutical industry’s increased focus on developing better treatments for many of today's most complex diseases should help it to grow for the foreseeable future. However, because highly priced pharma stocks are susceptible to anticipated market volatility in the near term, we ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Robinhood (NASDAQ: HOOD ) stock is catching flak on Wednesday as the company faces scrutiny for its “free share of stock” promotions. Source: mundissima / Shutterstock.com For those that don ...
Robinhood Markets (NASDAQ:HOOD) is getting some pressure for its marketing tactic of giving customers a free share of stock for opening an account or referring friends. The company is facing scrutiny from regulators and may have to shoulder the cost of distributing proxy materials to the shar...
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare di...
Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at $6.23, eclipsing its 52-week high. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 754,000 shares. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. ...
Image source: The Motley Fool. Catalyst Pharmaceuticals, inc (NASDAQ: CPRX) Q2 2021 Earnings Call Aug 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Catalyst Pharmaceuticals, inc (CPRX) Q2 2021 Earnings Call Tr...
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2021 Earnings Conference Call August 10, 2021 08:30 ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Jeffrey Del Car...
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million -$155.3 Million in Cash and Investments and no Funded Debt at End of Q2-2021 -Catalyst to Host Qu...
CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare di...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...